U.S. Specialty Stores Stock News

NasdaqCM:VKTX
NasdaqCM:VKTXBiotechs

Assessing Viking Therapeutics (VKTX) Valuation After Sharp Swings And Obesity Drug Optimism

Why Viking Therapeutics is on investors’ radar today Viking Therapeutics (VKTX) has drawn attention after recent trading left the stock with a past 3 months total return of 186.45% and a one year total return of 9.87%. See our latest analysis for Viking Therapeutics. The recent pullback, with a 7 day share price return of a 4.43% decline and a 90 day share price return of an 18.26% decline to US$31.51, sits against a much stronger 3 year total shareholder return of 186.45%. This suggests that...
NYSE:CAH
NYSE:CAHHealthcare

Cardinal Health (CAH) Valuation Check After Strong One Year Return And Recent Share Price Pullback

Cardinal Health (CAH) is back in focus after recent share price moves, with the stock closing at $216.02. For investors, the key question is how this current level aligns with the company’s fundamentals. See our latest analysis for Cardinal Health. The recent 1 day share price return of 3.21% decline and 7 day share price return of 4.89% decline come after a steadier period, with a 90 day share price return of 8.65% and a 1 year total shareholder return of 72.21%. This suggests longer term...
NasdaqGS:ZBRA
NasdaqGS:ZBRAElectronic

Zebra’s New Healthcare Tools And Valuation Gap Set Stage For HIMSS26

Zebra Technologies, NasdaqGS:ZBRA, has introduced its Orchestrated Care framework for healthcare. The company has also launched the DS82-HC Series scanner, focused on clinician workflows and patient safety. Both offerings are scheduled to be showcased at the HIMSS26 conference. Zebra Technologies is expanding its healthcare solutions with Orchestrated Care and the DS82-HC Series, integrating its hardware and software more closely with clinical workflows. The shares last closed at $229.67,...
NYSE:PBF
NYSE:PBFOil and Gas

Is PBF (PBF) Using Conferences And Dividends To Redefine Its Refining Resilience Narrative?

PBF Energy recently highlighted its participation at several major industry conferences, including the Wolfe Research Refining Conference and the 54th Annual Scotiabank Global Energy Conference, alongside confirming an upcoming dividend for Class A shareholders following strong fourth-quarter results. These events have drawn fresh attention to PBF’s operational outlook and capital return plans at a time when pipeline idling and refinery disruptions have raised questions about the resilience...
NYSE:RLX
NYSE:RLXTobacco

Does RLX (RLX) Extending Buybacks Reveal a New Capital Allocation and Innovation Playbook?

In early March 2026, RLX Technology announced it had reported unaudited fourth-quarter and full-year 2025 results and extended its existing share repurchase program by 24 months to December 31, 2027, supported by commentary on global expansion and new product launches. The decision to prolong buybacks while emphasizing innovation, compliance, and a more diversified product portfolio offers insight into how management is aligning capital allocation with its long-term business...
NYSE:RTX
NYSE:RTXAerospace & Defense

RTX Weighs Missile Demand Supply Risks And Hybrid Electric Progress

White House hosts RTX and other defense executives for urgent talks on accelerating weapons and missile production tied to the ongoing Middle East conflict and munitions shortages. RTX faces supply chain risk from a U.S. mandate to remove Chinese sourced rare earths from defense systems by 2027. The company secures a major contract for the UAE Patriot Program, expanding its role in regional air and missile defense. RTX reports a technological milestone with its hybrid electric aviation...
NasdaqGM:ALNT
NasdaqGM:ALNTElectrical

Is It Too Late To Consider Allient (ALNT) After A 146% One Year Rally?

If you are wondering whether Allient shares still offer value after a strong run, this article will walk through what the current price might be implying. The stock last closed at US$62.07, with returns of 11.7% year to date and 146.1% over the past year, even though the last 7 days and 30 days showed returns of a 7.5% decline and a 3.0% decline respectively. Recent attention on Allient has largely centered on its share price performance, with the strong 1 year return of 146.1% and 3 year...
NasdaqGS:ZG
NasdaqGS:ZGReal Estate

Zillow Group Buyback Authorization Adds New Layer To Capital Return Story

Zillow Group, ticker NasdaqGS:ZG, has approved a new share repurchase authorization of up to $1.25b. The buyback program signals the board's confidence in the company’s approach and long term plans. The authorization adds a fresh capital return tool that could influence how investors view the stock. Zillow Group is trading at $47.01, with the stock showing a 1.1% gain over the past week, a 19.9% decline over the past month, and a 28.3% decline year to date. Over a longer horizon, the shares...
NasdaqGM:OCUL
NasdaqGM:OCULPharmaceuticals

Assessing Ocular Therapeutix (OCUL) Valuation After Recent Share Price Volatility

Why Ocular Therapeutix (OCUL) Is On Investors’ Radar Today Ocular Therapeutix (OCUL) has drawn attention after recent trading brought its share price to US$10.33, with returns showing a mix of gains over the past month and year and declines in the past 3 months. See our latest analysis for Ocular Therapeutix. The recent 21.39% 1 month share price return contrasts with a 17.89% 3 month share price decline, while the 1 year total shareholder return of 40.74% hints at shifting sentiment around...
NasdaqGS:SRPT
NasdaqGS:SRPTBiotechs

Sarepta Therapeutics (SRPT) Is Down 7.0% After CEO Retirement Plan And ELEVIDYS Japan Launch News - Has The Bull Case Changed?

In late February 2026, Sarepta Therapeutics reported fourth-quarter 2025 revenue of US$442.93 million and a net loss of US$412.23 million, alongside CEO Douglas Ingram’s plan to retire by the end of 2026 or once a successor is appointed. At the same time, the commercial launch of ELEVIDYS in Japan through Chugai and supportive analyst commentary on Sarepta’s Duchenne muscular dystrophy franchise highlighted how new gene therapy access and external confidence are influencing expectations for...
NYSE:AA
NYSE:AAMetals and Mining

How Alcoa’s New External Affairs Chief Hire Will Impact Alcoa (AA) Investors

Alcoa Corporation recently announced that Emily Olson will join the company on April 6, 2026, as Executive Vice President and Chief External Affairs Officer, overseeing global government affairs, communications, stakeholder engagement, and the Alcoa Foundation as part of the Executive Team. Her deep background in sustainability, geopolitical risk and government relations across major resource companies such as Vale Base Metals, Freeport-McMoRan and BP suggests Alcoa is sharpening its focus...
NasdaqGS:JBLU
NasdaqGS:JBLUAirlines

JetBlue Expands Leisure Routes As Valuation Lags Analyst Targets

JetBlue Airways (NasdaqGS:JBLU) has launched new nonstop flights to Destin, Fort Walton Beach Airport from New York and Boston. The routes expand the airline's Florida network and connect key Northeast cities with the Emerald Coast region. JetBlue Vacations has introduced a "Great Weather Guarantee" for Jamaica vacation packages, tying trip bookings directly to weather conditions. For investors watching NasdaqGS:JBLU, these moves touch two core pieces of the business: domestic leisure...
NasdaqGS:AXON
NasdaqGS:AXONAerospace & Defense

How Axon’s AI-Driven Q4 Results and 2026 Outlook Could Reshape Axon Enterprise (AXON) Investors

In late February 2026, Axon Enterprise, Inc. reported fourth-quarter 2025 results showing revenue rising to US$796.72 million from US$575.15 million a year earlier, while net income declined to US$2.75 million from US$135.18 million, and issued full-year 2026 guidance calling for 27% to 30% year-over-year revenue growth. The results underscored Axon’s shift toward an AI- and software-centric public safety platform, with products like its Draft One report-writing tool and recent acquisitions...
NasdaqGS:BKR
NasdaqGS:BKREnergy Services

Is Baker Hughes (BKR) Still Attractively Priced After Its Recent Share Price Pullback

Wondering if Baker Hughes is still fairly priced after its strong run, or if the current share price is already baking in the story? This article looks at what the numbers say about value. The stock last closed at US$60.19, after a 7.3% decline over the past week, while its 30 day, year to date, 1 year and 5 year returns sit at 3.8%, 27.7%, 46.6% and 181.8% respectively. Recent coverage around Baker Hughes has focused on its role in the broader energy sector and how investors are weighing...
NYSE:KMI
NYSE:KMIOil and Gas

Is Kinder Morgan (KMI) Still Attractive After Strong Multi‑Year Share Price Gains

If you are wondering whether Kinder Morgan's current share price lines up with its underlying worth, you are not alone. That is exactly what this article will unpack. Over recent periods, Kinder Morgan's stock has closed at US$33.39, with returns of 1.0% over 7 days, 10.1% over 30 days, 20.5% year to date, 32.4% over 1 year, 128.5% over 3 years and 173.4% over 5 years. Recent news coverage has focused on Kinder Morgan as a core North American energy infrastructure company and its role in...
NYSE:MPLX
NYSE:MPLXOil and Gas

A Look At MPLX (MPLX) Valuation After Recent Multi Period Return Performance

MPLX (MPLX) has drawn attention after recent trading left the unit price near $58.66, with the partnership noting multi year total returns and operating a broad midstream footprint across U.S. pipelines, storage, and logistics. See our latest analysis for MPLX. At a share price of US$58.66, MPLX has seen a 6.13% 1 month share price return and 8.89% year to date share price return, while its 1 year total shareholder return of 21.30% and 5 year total shareholder return of 249.01% point to...
NYSE:LMND
NYSE:LMNDInsurance

Lemonade Shelf Registration And CFO Talk Put Dilution And Profitability In Focus

Lemonade (NYSE:LMND) filed a $190 million shelf registration, allowing it to potentially issue new securities over time. The company also confirmed its CFO will speak at a major technology conference, signaling fresh commentary on its business approach. These developments come as Lemonade shares most recently closed at $55.04. Lemonade, trading under NYSE:LMND, is drawing fresh attention with its new shelf registration and upcoming conference appearance. The stock last closed at $55.04,...
NYSE:VIK
NYSE:VIKHospitality

Is It Time To Reassess Viking Holdings (VIK) After A 60% One Year Share Price Gain

If you are trying to figure out whether Viking Holdings is still attractively priced or already reflecting a lot of optimism, you are in the right place. The stock last closed at US$72.17, with a 7 day return of 9.5% decline, a 30 day return of 2.2% decline, and a year to date move of 0.1% decline, while the 1 year return sits at 60.2%. Recent coverage around Viking has focused on its position within the travel and leisure space and on how investors are treating cruise and tour operators...
NYSE:O
NYSE:ORetail REITs

Realty Income Plans Legal Leadership Handover With M&A Execution In Focus

Realty Income (NYSE:O) announced that Executive Vice President and Chief Legal Officer Michelle Bushore will depart from the company following a defined transition period. Bushore has been closely involved in governance matters and major M&A transactions during her tenure. The company has outlined an orderly handover process to manage this leadership change. Realty Income, known for its monthly dividend model and focus on net lease real estate, has built its profile around long term rental...
NYSE:BTU
NYSE:BTUOil and Gas

Is It Too Late To Consider Peabody Energy (BTU) After Its 8x Five-Year Run?

Wondering if Peabody Energy at around US$33.28 is still offering value or if most of the easy gains are behind it? This article walks through what the current price might be implying. The stock has had a mixed short term run, with a 3.1% gain over the last week, a 5.5% decline over the last month, an 8.5% return year to date, and a very large return over the past 5 years that is close to 8x. These moves sit against a backdrop of ongoing attention on coal producers, as investors weigh the...
NYSE:AGX
NYSE:AGXConstruction

Assessing Argan (AGX) Valuation After A Short Term Share Price Pullback

What Argan’s recent share move means for investors Argan (AGX) shares closed at $430.25 after a mixed recent run, with a 7.1% decline over the past day and a 4.9% drop over the past week, despite longer term gains. For investors, that combination of short term weakness and stronger month and past 3 months performance raises a practical question: how does the current price line up with Argan’s fundamentals and recent business trends? See our latest analysis for Argan. Set against a strong...
NYSE:AZO
NYSE:AZOSpecialty Retail

A Look At AutoZone (AZO) Valuation After Q2 Sales Strength But Margin Pressure And Revenue Miss

AutoZone (AZO) just posted its fiscal second quarter, showing higher sales but thinner margins as inflation, product costs, and winter storms weighed on profitability and led to a revenue shortfall versus analyst expectations. See our latest analysis for AutoZone. AutoZone’s share price has been choppy around earnings, with a sharp drop on the Q2 miss followed by a rebound helped by renewed analyst optimism. However, the 90 day share price return of a 2.11% decline contrasts with a 5 year...
NasdaqGS:UTHR
NasdaqGS:UTHRBiotechs

Assessing United Therapeutics (UTHR) Valuation After Mixed Short-Term Returns And Strong Long-Term Gains

Why United Therapeutics Is On Investors’ Radar Today United Therapeutics (UTHR) is drawing attention after its share price closed at US$485.06, with returns mixed across recent periods, including a modest gain over the past month and a slight decline over the past 3 months. See our latest analysis for United Therapeutics. Recent trading has been choppy, with a 1 day share price return of a 1.05% decline and a 7 day share price return of a 3.68% decline. However, the 1 year total shareholder...
NYSE:AFG
NYSE:AFGInsurance

Record Underwriting Profit Amid Revenue Dip Might Change The Case For Investing In American Financial Group (AFG)

In its most recent quarter, American Financial Group reported earnings per share above analyst expectations despite a year-over-year revenue decline of 3.2%, reflecting strong underwriting results within its specialty property and casualty operations. Record underwriting profit, achieved even as reserve releases tightened and casualty loss assumptions became more conservative, highlights the resilience of AFG’s decentralized specialty insurance model compared with peers such as Octave...